Matteo Menotti

Matteo Menotti

Auto-generated profile, based on publicly available information

Matteo Menotti

Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2018 in Nature Medicine
Verified
Journal Article
Closed access
MMMatteo Menotti
Matteo Menotti
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
TCTaek-Chin Cheong
Taek-Chin Cheong
CPChiara Pighi
Chiara Pighi
IMInes Mota
Ines Mota
Roberto ChiarleRoberto Chiarle
Roberto Chiarle

1 December 2015 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
CVClaudia Voena
Claudia Voena
MMMatteo Menotti
Matteo Menotti
CMCristina Mastini
Cristina Mastini
FGFilomena Di Giacomo
Filomena Di Giacomo
DLDario Longo
Dario Longo
Roberto ChiarleRoberto Chiarle
Roberto Chiarle
Non–small cell lung cancer (NSCLC) harboring chromosomal rearrangements of the anaplastic lymphoma kinase (ALK) gene is treated with ALK tyrosine kinase inhibitors (TKI), but the treatment is successful for only a limited amount of time; most patients experience a relapse due to the development of drug resistance. Here, we show that a vaccine against ALK induced a strong and specific immune response that both prophylactically and therapeutically impaired the growth of ALK-positive lung tumors in mouse models. The ALK vaccine was efficacious also in combination with ALK TKI treatment and significantly delayed tumor relapses after TKI suspension. We found that lung tumors containing ALK rearrangements induced an immunosuppressive microenvironment, regulating the expression of PD-L1 on the surface of lung tumor cells. High PD-L1 expression reduced ALK vaccine efficacy, which could be restored by administration of anti–PD-1 immunotherapy. Thus, combinations of ALK vaccine with TKIs and immune checkpoint blockade therapies might represent a powerful strategy for the treatment of ALK-driven NSCLC. Cancer Immunol Res; 3(12); 1333–43. ©2015 AACR.

30 October 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CMCinzia Martinengo
Cinzia Martinengo
TPTeresa Poggio
Teresa Poggio
MMMatteo Menotti
Matteo Menotti
MSMaria Stella Scalzo
Maria Stella Scalzo
CMCristina Mastini
Cristina Mastini
Roberto ChiarleRoberto Chiarle
Roberto Chiarle
Rearrangements involving the anaplastic lymphoma kinase (ALK) gene are defining events in several tumors, including anaplastic large-cell lymphoma (ALCL) and non–small cell lung carcinoma (NSCLC). In such cancers, the oncogenic activity of ALK stimulates signaling pathways that induce cell transformation and promote tumor growth. In search for common pathways activated by oncogenic ALK across different tumors types, we found that hypoxia pathways were significantly enriched in ALK-rearranged ALCL and NSCLC, as compared with other types of T-cell lymphoma or EGFR- and K-RAS–mutated NSCLC, respectively. Consistently, in both ALCL and NSCLC, we found that under hypoxic conditions, ALK directly regulated the abundance of hypoxia-inducible factors (HIF), which are key players of the hypoxia response in normal tissues and cancers. In ALCL, the upregulation of HIF1α and HIF2α in hypoxic conditions required ALK activity and its downstream signaling proteins STAT3 and C/EBPβ. In vivo, ALK regulated VEGFA production and tumor angiogenesis in ALCL and NSCLC, and the treatment with the anti-VEGFA antibody bevacizumab strongly impaired ALCL growth in mouse xenografts. Finally, HIF2α, but not HIF1α, was required for ALCL growth in vivo whereas the growth and metastasis potential of ALK-rearranged NSCLC required both HIF1α and HIF2α. In conclusion, we uncovered an ALK-specific regulation of the hypoxia response across different ALK+ tumor types and propose HIFs as a powerful specific therapeutic target in ALK-rearranged ALCL and NSCLC. Cancer Res; 74(21); 6094–106. ©2014 AACR.

14 December 2015 in Oncogene
Verified
Journal Article
Closed access
PDF file
MCM Ceccon
M Ceccon
MMM E Boggio Merlo
M E Boggio Merlo
LML Mologni
L Mologni
TPTeresa Poggio
Teresa Poggio
LVL M Varesio
L M Varesio
CVC Voena
C Voena

10 July 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
IMInes Mota
Ines Mota
EPEnrico Patrucco
Enrico Patrucco
CMCristina Mastini
Cristina Mastini
NMNavin R. Mahadevan
Navin R. Mahadevan
TTTran C. Thai
Tran C. Thai
Roberto ChiarleRoberto Chiarle
Roberto Chiarle

23 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
CVClaudia Voena
Claudia Voena
LVLydia M. Varesio
Lydia M. Varesio
LZLiye Zhang
Liye Zhang
MMMatteo Menotti
Matteo Menotti
TPTeresa Poggio
Teresa Poggio
Roberto ChiarleRoberto Chiarle
Roberto Chiarle
Https://doi.org/10.18632/oncotarget.8955 Claudia Voena, Lydia M. Varesio, Liye Zhang, Matteo Menotti, Teresa Poggio, Elena Panizza, Qi Wang, Valerio G. Minero, Sharmila Fagoonee, Mara Compagno,...